Expert Recommendations for the Diagnosis and Treatment of Axial Spondyloarthritis
  • CME

In this interactive multimedia presentation, gain expert insights on current guidelines and best practice for your patients with axial spondyloarthritis.
Atul Deodhar, MD
Program Director
M. Susan Burke, MD, FACP
Marina N. Magrey, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: July 30, 2020 Expiration: July 29, 2021
Multimedia Expert Recommendations for the Diagnosis and Treatment of Axial Spondyloarthritis
This program is divided into short segments that you can review from the Activity landing page. After reviewing all segments, click the Claim Credit button to complete the CME posttest and evaluation.
Overview
Meet the experts leading this dynamic, interactive activity.
Launch Overview
Diagnosis
Case-based discussion on diagnostic approaches for suspected axial spondyloarthritis.
Launch Diagnosis
Role of MRI
Learn how to properly employ MRI in suspected axial spondyloarthritis.
Launch Role of MRI
Prevalence, Referral
Hear the experts discuss how common axial spondyloarthritis is in the US and when to refer to a rheumatologist.
Launch Prevalence, Referral
Treatment
Follow the case to explore recommended treatment options.
Launch Treatment
Comorbidities
Review common comorbidities in patients with axial spondyloarthritis.
Launch Comorbidities
Emerging Treatments
Gain expert insights on investigational treatments currently in phase II/III trials for axial spondyloarthritis.
Launch Emerging Treatments
Conclusions
Review the take-home points from this activity.
Launch Conclusions

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the evaluation of patients who may have axSpA including clinical presentation, laboratory studies, and appropriate imaging studies to improve early diagnosis
  • Review the ASAS classification criteria for axSpA
  • Discuss extra-articular manifestations and QoL concerns seen in patients with axSpA
  • Apply the guideline recommendations for the management of axSpA
  • Describe agents in late-stage development for axSpA

Acknowledgements

Provided by Purdue University College of Pharmacy
Purdue University Logo

Accreditation: Dawn Sinclair, Purdue University sinclaid@purdue.edu
Certificates/Credits: Heather Holley, Purdue University hholley@purdue.edu

This activity is supported by educational funding provided by
AbbVie Inc.
Novartis Pharmaceuticals Corporation

Information on this Educational Activity

All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of Clinical Care Options, LLC and Purdue University College of Pharmacy have no relationships to disclose,

Program Director

Atul Deodhar, MD
Professor of Medicine
Medical Director
, Rheumatology Clinics
Division of Arthritis and Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon
Atul Deodhar, MD, has disclosed that he has received consulting fees from and has served on advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Galapagos, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, and UCB and has received funds for research support from AbbVie, GlaxoSmithKline, Lilly, Novartis, Pfizer, and UCB.

Faculty

M. Susan Burke, MD, FACP

Clinical Associate Professor of Medicine
Department of Internal Medicine
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, Pennsylvania
Senior Advisor
Lankenau Medical Associates
Lankenau Medical Center
Wynnewood, Pennsylvania

M. Susan Burke, MD, FACP, has no relevant conflicts of interest to report.
Marina N. Magrey, MD

Associate Professor of Medicine
Division of Rheumatology
Department of Medicine
Case Western Reserve University School of Medicine
Director, Rheumatology Fellowship
MetroHealth Medical Center
Cleveland, Ohio

Marina N. Magrey, MD, has disclosed that she has received consulting fees from and has served on advisory boards for Janssen, Lilly, Novartis, Pfizer, and UCB and has received funds for research support from AbbVie and UCB.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Pranali Pathare, PhD

Editorial Contributor

Pranali Pathare, PhD, has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

Target Audience

This educational activity is intended for rheumatologists, primary care physicians, and other clinicians managing patients with axSpA.

Goal

The goal of this activity is to increase the knowledge and competence in diagnosing and managing axSpA (including differentiating nr-axSpA and AS and applying current guidelines based on new and emerging therapies) among rheumatology and primary care clinicians.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and Clinical Care Options, LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 30, 2020, through July 29, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Free editable slides from CCO: best practice for diagnosis and treatment of axial spondyloarthritis. With Drs. Susan Burke, Atul Deodhar, Marina N. Magrey

Atul Deodhar, MD
Program Director
M. Susan Burke, MD, FACP Marina N. Magrey, MD
Released: July 30, 2020

Despite demonstration of comparable efficacy and safety between biosimilars and their originators, some patients avoid this treatment switch. Here’s my take on steps to assuage unfounded patient fears.

Jonathan Kay, MD Released: February 13, 2018

Watch our recent quiz game on biosimilars in rheumatologic conditions.

Stanley B. Cohen, MD Jonathan Kay, MD Kenneth G. Saag, MD, MSc Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: November 28, 2017 Expired: November 27, 2018

In this downloadable slideset, Jonathan Kay, MD, explores key concepts including immunogenicity, switching, and interchangeability of biosimilars.

Stanley B. Cohen, MD Jonathan Kay, MD Kenneth G. Saag, MD, MSc Released: November 21, 2017

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?